2017 Fiscal Year Final Research Report
Identification of imatinib resistance factor and the therapeutic strategies to overcome resistance in chronic myeloid leukemia
| Project/Area Number |
15K08116
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Kindai University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
TSUBAKI Masanobu 近畿大学, 薬学部, 准教授 (30434856)
TAKEDA Tomoya 近畿大学, 薬学部, 助教 (20734031)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Keywords | 慢性骨髄性白血病 / イマチニブ / BCR-ABL阻害薬 |
|---|
| Outline of Final Research Achievements |
To investigate the underlying mechanisms associated with resistance to imatinib, we established imatinib-resistant chronic myeloid leukemia (CML) cell lines. The resistant cell lines activation of MET. In addition, MET inhibitor reversed the imatinib-resistance of the drug-resistant cell lines. These findings suggest that MET inhibitors are potentially useful as an imatinib-resistance CML agent for the treatment of CML cells.
As well, These results are summarized as section of presented paper.
|
| Free Research Field |
医療薬学
|
